Business Overview: Gain Therapeutics, Inc. (NASDAQ: GANX)

---

Executive Summary

Gain Therapeutics, Inc. is a biotechnology company developing small-molecule therapeutics for central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and protein-degradation-treatable diseases such as oncology. The company's pipeline is built entirely around its proprietary Magellan™ computational discovery platform.

Its lead program, GT-02287, targets Parkinson's disease (with or without a GBA1 mutation) and is currently in a Phase 1b clinical study, with Part 1 completed in November 2025 and Part 2 expected to finish in Q3 2026, ahead of a planned Phase 2 study later that year.

---

1. Core Business Model & How They Work

[ Magellan™ Platform: Allosteric Site Discovery ] ➡️ [ STAR Small-Molecule Design ] ➡️ [ Preclinical Validation ] ➡️ [ Clinical Trials ] ➡️ [ Partnership / Approval ]

• Gain Therapeutics' entire pipeline originates from Magellan™, a computational platform that identifies allosteric binding sites on disease-related proteins — sites away from a protein's main active site — and designs small molecules ("structurally targeted allosteric regulators," or STARs) that bind them.
• The company argues allosteric targeting offers greater specificity, better drug-like properties, and the potential to reach hard-to-treat tissue, including across the blood-brain barrier — directly relevant to its CNS-focused pipeline.
• As a clinical-stage company, its business model is R&D-driven: advance GT-02287 and other Magellan-derived candidates through trials, while pursuing academic and industry collaborations to extend the platform's reach without funding every program internally.

---

2. Business Segments

Gain Therapeutics operates as a single clinical-stage R&D business; this section is omitted in favor of a pipeline breakdown.

                      ┌─────────────────────────────┐
                      │        Magellan™ Platform       │
                      └───────────────┬─────────────────┘
                                      │
        ┌──────────────────────────────┼──────────────────────────────┐
        ▼                               ▼                               ▼
┌─────────────────────┐     ┌─────────────────────────┐     ┌─────────────────────┐
│  GT-02287 (Parkinson's)│     │  Gaucher Disease /          │     │  Dementia with Lewy   │
│  Phase 1b ongoing       │     │  Lysosomal Storage           │     │  Bodies / Alzheimer's  │
│                         │     │  Disorders (early)           │     │  (early)                │
└─────────────────────┘     └─────────────────────────┘     └─────────────────────┘

---

3. Product Portfolio (Pipeline)

---

4. Competitive Landscape

• In Parkinson's disease, Gain Therapeutics' GBA1-targeted, GCase-restoring mechanism competes against both large pharmaceutical companies' broader Parkinson's pipelines and other biotechs pursuing GBA1/glucocerebrosidase-related approaches.
• The allosteric drug-discovery approach itself competes with other computational and structure-based discovery platforms used across the biotech industry, though few rivals are focused as specifically on allosteric sites.
• In lysosomal storage disorders more broadly, established enzyme-replacement-therapy competitors have long dominated conditions like Gaucher disease, meaning any small-molecule challenger must demonstrate a meaningfully differentiated profile.

             Established Therapy Classes
                        │
          ● Enzyme replacement therapy (Gaucher, LSDs)
          ● Large pharma Parkinson's pipelines
                        │
   ─────────────────────┼───────────────────────────
                        │
          ● Gain Therapeutics (Magellan™ allosteric small molecules)
                        │
             Platform-Driven Discovery Challengers

---

5. Strategic Strengths & Risks

Strengths

• A proprietary, broadly applicable discovery platform (Magellan™) that has already generated a clinical-stage CNS candidate, suggesting the technology can produce more than a single asset.
• Encouraging early biomarker data (53% increase in GCase activity at the highest dose) supporting the mechanistic thesis behind GT-02287.
• A capital-efficient model that uses academic and industry collaborations to extend the platform's reach beyond what Gain Therapeutics could fund alone.
• Multiple potential indications (Parkinson's, Gaucher disease, dementia with Lewy bodies, Alzheimer's) for the same core asset and mechanism, creating option value from one clinical program.

Risks

• GT-02287 is still in Phase 1b, multiple stages away from any approval decision; Parkinson's disease trials are historically long, expensive, and prone to high failure rates.
• As with any clinical-stage biotech, the company faces an explicitly disclosed risk around its "ability to continue as a going concern and...needs for additional financing" in its forward-looking-statement risk topics, even though no going-concern qualification appears in the Item 1 excerpt itself.
• Competing against both large pharma Parkinson's programs and established Gaucher-disease enzyme-replacement therapies means Gain Therapeutics must prove meaningful differentiation, not just mechanistic novelty.
• Reliance on a single lead platform (Magellan™) and a single lead clinical candidate concentrates company value in one mechanism's clinical success.

---

6. Financial Overview

Note: Gain Therapeutics' Item 1 Business disclosure focuses on pipeline and platform description rather than financial statements; cash position and burn rate are reported elsewhere in the 10-K.

---

7. Summary Conclusion

Gain Therapeutics has built a differentiated computational discovery platform in Magellan™ and translated it into a clinical-stage Parkinson's disease candidate, GT-02287, with early biomarker data supporting the mechanism and a Phase 1b study now nearing completion. The platform's ability to generate multiple indications from one lead asset — spanning Parkinson's, Gaucher disease, and other neurodegenerative conditions — offers real optionality for a small biotech. The biggest forward risk is the combination of early clinical stage and financing uncertainty: Parkinson's disease development is notoriously long and expensive, and the company's own risk disclosures flag additional-financing needs that will have to be resolved well before GT-02287 could reach a Phase 2 readout capable of supporting further investment or a partnership.